Alkermes Inc (ALKS) investors sentiment increased to 1.15 in Q1 2018. It’s up 0.40, from 0.75 in 2017Q4. The ratio is positive, as 102 investment professionals opened new and increased equity positions, while 89 sold and decreased holdings in Alkermes Inc. The investment professionals in our database now have: 152.74 million shares, up from 152.34 million shares in 2017Q4. Also, the number of investment professionals holding Alkermes Inc in top ten equity positions increased from 1 to 2 for an increase of 1. Sold All: 17 Reduced: 72 Increased: 61 New Position: 41.
The stock of Unisys Corporation (NYSE:UIS) is a huge mover today! The stock decreased 2.60% or $0.35 during the last trading session, reaching $13.1. About 123,901 shares traded. Unisys Corporation (NYSE:UIS) has declined 3.63% since June 14, 2017 and is downtrending. It has underperformed by 16.20% the S&P500. Some Historical UIS News: ; 01/05/2018 – Unisys Backs 2018 Rev $2.75B-$2.875B; 01/05/2018 – UNISYS REAFFIRMS FULL-YEAR GUIDANCE; 09/05/2018 – NIHON UNISYS 8056.T 2017/18 GROUP NET PROFIT 11.95 BLN YEN (+16.4 %), 2018/19 FORECAST PROFIT 12.50 BLN YEN (+4.6 %); 29/03/2018 – Unisys Survey of Banking Professionals Finds Digital Transformation in Retail Banking Still Lagging in Key Areas; 01/05/2018 – UNISYS 1Q ADJ EPS 19C, EST. 20C; 09/05/2018 – U.S. Customs and Border Protection Awards Contract to Unisys to Help Agency Assess Potential Threats from Travelers and Cargo C; 02/04/2018 – Unisys Names Katie Ebrahimi as Senior Vice President and Chief Human Resources Officer; 17/04/2018 – Flowserve Expands Use of Unisys Stealth® Microsegmentation; 30/04/2018 – Transportation Security Administration Selects Unisys to Secure, Operate, Maintain and Protect Screening Equipment in U.S. Airp; 19/03/2018 – Unisys to Help the Department of Home Affairs Secure Australia’s Borders and Facilitate Flow of Legitimate Travelers Using Unisys Stealth(identity)™ BiometricsThe move comes after 8 months negative chart setup for the $667.64M company. It was reported on Jun, 14 by Barchart.com. We have $11.92 PT which if reached, will make NYSE:UIS worth $60.09M less.
The stock increased 3.09% or $1.515 during the last trading session, reaching $50.505. About 520,987 shares traded. Alkermes plc (ALKS) has declined 21.00% since June 14, 2017 and is downtrending. It has underperformed by 33.57% the S&P500. Some Historical ALKS News: ; 30/05/2018 – Alkermes Closes Above 50-Day Moving Average: Technicals; 16/04/2018 – ALKERMES – ALKS 5461 NDA FILING BASED ON RESULTS FROM A CLINICAL EFFICACY AND SAFETY PACKAGE; 04/05/2018 – PRESS RELEASE ALKERMES LAUNCHES AWARD PROGRAM TO SUPPORT AND ADVANCE CENTRAL NERVOUS SYSTEM DISORDERS RESEARCH; 19/04/2018 – Alkermes to Host Conference Call to Discuss First Quarter 2018 Financial Results; 10/04/2018 – Alkermes at Deutsche Bank Health Care Conference May 9; 08/05/2018 – Atlas Obscura: Alkermes is a syrupy, spicy liqueur whose bright red color originally came from an unusual source: the scales of; 16/04/2018 – Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depres; 11/05/2018 – ALKS 3831 (Alkermes) Drug Overview to 2026 with Phase lll Data & Trials – ResearchAndMarkets.com; 02/04/2018 – ALKERMES PLC SAYS “STRONGLY DISAGREES WITH FDA’S CONCLUSIONS AND PLANS TO APPEAL FDA’S DECISION”; 29/03/2018 – ALKERMES SAYS AMENDMENT PROVIDES FOR NEW CLASS OF REPLACEMENT TERM LOANS OF $284.3 MLN MATURING ON MARCH 26, 2023 – SEC FILING
Analysts await Alkermes plc (NASDAQ:ALKS) to report earnings on July, 26. They expect $-0.28 earnings per share, down 115.38% or $0.15 from last year’s $-0.13 per share. After $-0.20 actual earnings per share reported by Alkermes plc for the previous quarter, Wall Street now forecasts 40.00% negative EPS growth.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company has market cap of $7.83 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It currently has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.
Meditor Group Ltd holds 9.4% of its portfolio in Alkermes plc for 1.03 million shares. Opus Point Partners Management Llc owns 24,333 shares or 2.77% of their US portfolio. Moreover, Roanoke Asset Management Corp Ny has 1.69% invested in the company for 60,536 shares. The New Mexico-based Thornburg Investment Management Inc has invested 1.37% in the stock. Timpani Capital Management Llc, a Wisconsin-based fund reported 59,311 shares.
More notable recent Alkermes plc (NASDAQ:ALKS) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on June 06, 2018, also Streetinsider.com with their article: “Alkermes (ALKS) Receives $50M Payment From Biogen (BIIB) Following Review of Prelim. Data From Ongoing …” published on June 06, 2018, Seekingalpha.com published: “FDA OKs first non-opioid treatment for opioid withdrawal” on May 16, 2018. More interesting news about Alkermes plc (NASDAQ:ALKS) were released by: Globenewswire.com and their article: “Detailed Research: Economic Perspectives on Bank of Nova Scotia, Eaton Corporation, Canadian National Railway …” published on June 04, 2018 as well as Benzinga.com‘s news article titled: “Benzinga Pro’s 5 Stocks To Watch Today” with publication date: June 07, 2018.
Ratings analysis reveals 100% of Alkermes’s analysts are positive. Out of 3 Wall Street analysts rating Alkermes, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $70.0 while the high is $70.0. The stock’s average target of $70 is 38.60% above today’s ($50.505) share price. ALKS was included in 3 notes of analysts from October 21, 2016. Leerink Swann maintained the shares of ALKS in report on Friday, October 21 with “Outperform” rating. As per Friday, October 21, the company rating was upgraded by JP Morgan. The firm earned “Buy” rating on Friday, October 21 by Jefferies.
Since May 9, 2018, it had 0 insider buys, and 2 selling transactions for $96,595 activity. El Sadany Tarek sold $908 worth of stock or 75 shares. Shares for $95,687 were sold by RENZI JEFFREY on Wednesday, May 9.
Among 5 analysts covering Unisys Corporation (NYSE:UIS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Unisys Corporation has $19 highest and $9 lowest target. $14.33’s average target is 9.39% above currents $13.1 stock price. Unisys Corporation had 8 analyst reports since December 22, 2015 according to SRatingsIntel. The stock of Unisys Corporation (NYSE:UIS) earned “Buy” rating by SunTrust on Tuesday, October 31. Susquehanna downgraded the shares of UIS in report on Monday, February 12 to “Neutral” rating. The firm has “Hold” rating by Loop Capital given on Tuesday, October 31. Sidoti initiated the stock with “Buy” rating in Tuesday, March 29 report. The firm has “Buy” rating given on Wednesday, June 22 by Suntrust Robinson. Loop Capital initiated Unisys Corporation (NYSE:UIS) on Tuesday, January 10 with “Hold” rating.
More news for Unisys Corporation (NYSE:UIS) were recently published by: Prnewswire.com, which released: “Malaysian Bank Customers Ready to Embrace Artificial Intelligence and Automation in Digital Banking – Unisys …” on June 13, 2018. Prnewswire.com‘s article titled: “Healthcare Providers Cite Struggles with Medical Device Security, Data Management — Unisys Survey” and published on June 05, 2018 is yet another important article.
Analysts await Unisys Corporation (NYSE:UIS) to report earnings on August, 7. They expect $0.27 earnings per share, up 800.00% or $0.24 from last year’s $0.03 per share. UIS’s profit will be $13.76 million for 12.13 P/E if the $0.27 EPS becomes a reality. After $0.19 actual earnings per share reported by Unisys Corporation for the previous quarter, Wall Street now forecasts 42.11% EPS growth.
Unisys Corporation provides information technology services worldwide. The company has market cap of $667.64 million. It operates through two divisions, Services and Technology. It currently has negative earnings. The Services segment provides cloud and infrastructure services, application services, and business process outsourcing services.
Investors sentiment increased to 1.19 in 2018 Q1. Its up 0.10, from 1.09 in 2017Q4. It improved, as 7 investors sold Unisys Corporation shares while 50 reduced holdings. 34 funds opened positions while 34 raised stakes. 57.23 million shares or 0.75% more from 56.80 million shares in 2017Q4 were reported. Citadel Advsr Ltd Co reported 153,733 shares. Ameritas Investment Partners reported 3,852 shares. Geode Capital Mgmt Ltd Liability accumulated 443,097 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its portfolio in Unisys Corporation (NYSE:UIS) for 1,390 shares. Cambridge Invest Rech has 71,242 shares for 0.01% of their portfolio. 699 are held by Tower Rech Capital Limited Liability Company (Trc). Bnp Paribas Asset Management Holdings stated it has 0.02% of its portfolio in Unisys Corporation (NYSE:UIS). Northern Tru has 603,178 shares. Parametric Portfolio Assoc Lc invested 0% of its portfolio in Unisys Corporation (NYSE:UIS). 724 are owned by Stratos Wealth Ptnrs. Wellington Mgmt Gp Llp has 62,024 shares for 0% of their portfolio. Millennium Ltd Llc holds 0.01% or 830,903 shares in its portfolio. Ftb Advsr Incorporated reported 0% in Unisys Corporation (NYSE:UIS). Walleye Trading Lc reported 0% in Unisys Corporation (NYSE:UIS). Credit Suisse Ag stated it has 484,429 shares.